Get the Stockscreener App
133.94
0.70%
-0.745
Axsome Therapeutics Inc stock is traded at $133.94, with a volume of 43,547.
It is down -0.70% in the last 24 hours and up +14.54% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$134.68
Open:
$133.55
24h Volume:
43,547
Relative Volume:
0.08
Market Cap:
$6.68B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-20.51
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+1.79%
1M Performance:
+14.54%
6M Performance:
+24.71%
1Y Performance:
+48.42%
1-Day Range:
$132.61
$134.58
1-Week Range:
$126.80
$134.99
52-Week Range:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
133.94 | 6.72B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.92 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.56 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.45 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
833.61 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.92 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
How rising interest rates impact Axsome Therapeutics Inc. stockEarnings Miss & Technical Entry and Exit Alerts - newser.com
Historical volatility pattern of Axsome Therapeutics Inc. visualized2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
Can machine learning forecast Axsome Therapeutics Inc. recoveryEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
Market reaction to Axsome Therapeutics Inc.’s recent news2025 Bull vs Bear & Smart Money Movement Tracker - newser.com
Peregrine Capital Management LLC Acquires 13,747 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc. stock trend forecastInsider Selling & Stock Portfolio Risk Management - newser.com
How Axsome Therapeutics Inc. stock performs in rate cut cyclesWeekly Investment Summary & Expert Approved Trade Ideas - newser.com
Has Axsome Therapeutics Inc. formed a bullish divergenceMarket Sentiment Report & Short-Term High Return Strategies - newser.com
Can Axsome Therapeutics Inc. stock continue upward trendJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com
Allianz Asset Management GmbH Increases Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc. stock volume spike explainedJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com
How Axsome Therapeutics Inc. stock compares to market leaders2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Is Axsome Therapeutics Inc. stock attractive after correctionWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Is Axsome Therapeutics Inc. stock a buy on dipsJuly 2025 Levels & Community Trade Idea Sharing Platform - newser.com
How supply chain issues affect Axsome Therapeutics Inc. stock2025 Winners & Losers & Weekly Stock Performance Updates - Fundação Cultural do Pará
How Axsome Therapeutics Inc. (19X) stock reacts to Fed tightening2025 Top Gainers & Smart Allocation Stock Tips - newser.com
Bull Bear: Is Axsome Therapeutics Inc. stock a top pick in earnings seasonQuarterly Growth Report & Fast Moving Trade Plans - Fundação Cultural do Pará
Tools to assess Axsome Therapeutics Inc.’s risk profile2025 Winners & Losers & Risk Managed Investment Strategies - newser.com
Is a relief rally coming for Axsome Therapeutics Inc. holdersCPI Data & Low Volatility Stock Recommendations - newser.com
Is Axsome Therapeutics Inc. stock gaining market sharePortfolio Risk Summary & Reliable Price Action Trade Plans - newser.com
What Wall Street predicts for Axsome Therapeutics Inc. stock priceTrade Performance Summary & Low Volatility Stock Suggestions - newser.com
Axsome Therapeutics Advances Study on Solriamfetol for Binge Eating Disorder - TipRanks
Axsome Therapeutics’ AXS-05 Study: A Potential Game-Changer for MDD Relapse Prevention - TipRanks
Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - sharewise.com
What candlestick patterns are forming on Axsome Therapeutics Inc.Earnings Summary Report & Stepwise Trade Signal Implementation - newser.com
Is Axsome Therapeutics Inc. forming a reversal patternGold Moves & Low Risk High Reward Ideas - newser.com
Axsome Therapeutics (AXSM) Projected to Post Earnings on Monday - MarketBeat
Surprises Report: How rising interest rates impact Axsome Therapeutics Inc. stockJuly 2025 Recap & Fast Moving Market Watchlists - Fundação Cultural do Pará
Published on: 2025-10-27 05:40:44 - newser.com
2,100 Shares in Axsome Therapeutics, Inc. $AXSM Bought by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Option Exercise |
8.02 |
13,390 |
107,388 |
20,619 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Option Exercise |
8.02 |
12,774 |
102,447 |
20,003 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Sale |
120.17 |
19,220 |
2,309,667 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Sale |
118.77 |
13,390 |
1,590,330 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Sale |
118.84 |
12,774 |
1,518,062 |
7,229 |
2.12%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):